Vis enkel innførsel

dc.contributor.authorOppen, Kjersti
dc.contributor.authorUeland, Thor
dc.contributor.authorMichelsen, Annika Elisabet
dc.contributor.authorAukrust, Pål
dc.contributor.authorSteinsvik, Trude
dc.contributor.authorSkadberg, Øyvind
dc.contributor.authorBrede, Cato
dc.contributor.authorSiljan, William Ward
dc.contributor.authorHusebye, Einar
dc.contributor.authorHolter, Jan Cato
dc.contributor.authorHeggelund, Lars
dc.date.accessioned2022-06-01T08:32:58Z
dc.date.available2022-06-01T08:32:58Z
dc.date.issued2022-01-20
dc.description.abstractBackground: Virtually all living organisms, including microbes and humans, depend on iron to survive and grow. During an infection, the plasma level of iron and several iron-related proteins change substantially. We hypothesized that iron and iron-related proteins could predict short- and long-term outcomes in community-acquired pneumonia.<p> <p>Methods: Blood samples from a prospective cohort of 267 in-patients with community-acquired pneumonia were analysed for hepcidin, ferritin, iron, transferrin, transferrin saturation, and soluble transferrin receptor at admission and 6-weeks postdischarge. Adverse short-term outcome was defined as admission to intensive care unit or death within 30 days, and longterm outcome was assessed as 5-year overall mortality. Logistic regression, Kaplan Meier survival curves, and Cox regression models with cut-offs at median for the potential biomarkers were used for statistical evaluation. <p>Results: Low admission levels of hepcidin predicted 5-year overall mortality, independently of age, sex, comorbid conditions, and anaemia. Low levels of ferritin at admission as well as low levels of iron and transferrin saturation and high levels of soluble transferrin receptor at the 6-week follow-up were predictors of 5-year overall mortality in univariable, but not in multivariable analyses. Neither of these potential biomarkers predicted adverse short-term outcomes. <p>Conclusions: In hospitalized patients with community-acquired pneumonia, low levels of hepcidin at admission predicted 5-year overall mortality, but not short-term adverse outcome.en_US
dc.identifier.citationKjersti Oppen, Thor Ueland, Annika E. Michelsen, Pål Aukrust, Trude Steinsvik, Øyvind Skadberg, Cato Brede, William Ward Siljan, Einar Husebye, Jan Cato Holter & Lars Heggelund (2022) Hepcidin predicts 5-year mortality after community-acquired pneumonia, Infectious Diseases, 54:6, 403-409en_US
dc.identifier.cristinIDFRIDAID 2023846
dc.identifier.doi10.1080/23744235.2021.2022194
dc.identifier.issn2374-4235
dc.identifier.issn2374-4243
dc.identifier.urihttps://hdl.handle.net/10037/25340
dc.language.isoengen_US
dc.publisherTaylor & Francisen_US
dc.relation.journalInfectious Diseases
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.titleHepcidin predicts 5-year mortality after community-acquired pneumoniaen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel